Ethics in research: Bend it like Beauchamp

Journal of Extra-Corporeal Technology

Volumn 38, Issue 4, 2006, Pages 312-317

  Merry, Alan F ^a   Merry, David ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; VALDECOXIB;

ARTHRITIS; CHRONIC PAIN; CONFERENCE PAPER; DEONTOLOGY; DRUG INDUSTRY; DRUG SAFETY; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEALTH CARE; HEART INFARCTION; HUMAN; HYPOTHESIS; MEDICAL RESEARCH; MORALITY; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PAIN; PUBLISHING; RESEARCH ETHICS; RHEUMATOID ARTHRITIS; RISK REDUCTION; STATISTICAL ANALYSIS; ULCER;

EID: 41949104038     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. le Carré J. The Constant Gardener. New York: Scribner; 2001.
2. Gordi T, Khamis H. Simple solution to a common statistical problem: Interpreting multiple tests. Clin Ther. 2004;26:780-6.
3. Bender R, Lange S. Adjusting for multiple testing - when and how? J Clin Epidemiol. 2001;54:343-9.
4. Altman DG. Practical Statistics for Medical Research. 1st ed. London: Chapman and Hall; 1991.
5. Rachels J. The Elements of Moral Philosophy. 4th ed. Boston: McGraw Hill; 2003.
6. Hursthouse R. On Virtue Ethics. Oxford: Oxford University Press; 1999.
7. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247-55.
8. Juni P, Rutjes AWS, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?: Adequate analysis of the CLASS trial indicates that this may not be the case. BMJ. 2002;324:1287-8.
9. Wright J, Perry T, Bassett K, Chambers G. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA. 2001;286:2398-400.
10. Jenkins JK, Seligman P. Memorandum. Rockville, MD: Food and Drug Administration; 2005.
11. Miller FG, Brody H. Viewpoint: professional integrity in industry-sponsored clinical trials. Acad Med. 2005;80:899-904.
12. Hrachovec J, Mora M, Wright JM, et al. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA. 2001;286:2398-400.
13. Silverstein FMD, Simon LMD, Faich GMD. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA. 2001;286:2398-400.
14. Dieppe PA, Ebrahim S, Martin RM, Juni P. Lessons from the withdrawal of rofecoxib. BMJ. 2004;329:867-8.
15. Chibnall JT, Jeral JM, Cerullo MA. Experiments on distant intercessory prayer: God, science, and the lesson of Massah. Arch Intern Med. 2001;161:2529-36.
16. Beauchamp T, Childress J. Principles of Biomedical Ethics. 4th ed. New York: Oxford University Pressl 1994.